Tesofensine

Tesofensine – Benefits & Side Effects

Tesofensine – Protocol

Tesofensine – Lifestyle Considerations

Proper Peptide Storage

Why Proper Peptide Storage Matters

Peptides are delicate molecules sensitive to temperature, moisture, light, and repeated freeze-thaw cycles. Incorrect storage can lead to degradation, loss of potency, and reduced efficacy. Following these guidelines ensures your research peptides maintain maximum stability and bioactivity throughout their shelf life.

Lyophilized (Powder) Peptides

Optimal Storage:

• Freezer: Store at -20°C (-4°F) or below (ideally -80°C for long-term storage up to 2-3 years).
• Short-term: Refrigerate at 2-8°C (35.6-46.4°F) for weeks to months.
• Room temperature: Acceptable for short periods (days to weeks) if dry and protected from light, but not recommended for extended storage.
• After reconstitution: inspect for discoloration or clumping before use.

Key Practices:

• Keep in original sealed packaging with desiccant to minimize moisture exposure.
• Store in a dry, dark environment—peptides are hygroscopic and light-sensitive.
• Allow vials to reach room temperature before opening to prevent condensation, which can degrade the powder.

Reconstituted (Liquid) Peptides

Refrigeration is Essential:

• Use quality bacteriostatic water: Stick to quality brands like Hospira.
• Store at 2-8°C (35.6-46.4°F) immediately after reconstitution.
• Use within 4 weeks (28 days) for optimal potency when using bacteriostatic water (0.9% benzyl alcohol).
• Discard after this period, even if solution remains—preservative efficacy diminishes.

Important Warnings:

• Do NOT freeze reconstituted solutions—freezing denatures peptides.
• Avoid freeze-thaw cycles—they cause irreversible degradation. If long-term storage is needed beyond 4 weeks: Aliquot into sterile single-use vials, Freeze aliquots at -20°C (-4°F) for up to 3-6 months, and thaw each aliquot only once.

Handling Peptides Best Practices

1. Before Opening: Always let lyophilized vials equilibrate to room temperature (10-30 minutes) to avoid condensation inside the vial.
2. Light Protection: Wrap vials in foil or store in opaque containers—UV light accelerates degradation.
3. Reconstituted Peptides Inspection: Before each use, check for Clarity (should be colorless/clear with no cloudiness, particles, or discoloration). Discard if any issues observed.
4. Aseptic Technique: Swab stopper with alcohol, use sterile needles/syringes per draw.
5. Labeling: Mark reconstitution date on vials.

Common Peptide Storage Mistakes to Avoid

• Moisture Exposure: Never store open vials; always reseal tightly.
• Temperature Fluctuations: Avoid door storage in fridge/freezer.
• Heat/Light: Keep away from direct sunlight, heaters, or lab lights.
• Overuse of Multi-Dose Vials: Follow 28-day rule per USP/CDC guidelines.
• Freezing Liquids: Repeated cycles can reduce potency by 25%+ per cycle.

Special Peptide Considerations

• Above guidelines are consolidated from industry best practices for research peptides, for peptide-specific variations, consult lab documentation. Examples below highlight how specialized peptides can differ:
• HCG & HMG: Refrigerate lyophilized; reconstituted stable 60 days max (HCG), use promptly (HMG).
• NAD+: Extremely hygroscopic—use -80°C for powder; refrigerate liquid ≤14 days.
• PT-141: Room temp stable short-term; refrigerate reconstituted ≤1 week.

Subcutaneous Peptide Injection Protocol

Subcutaneous Peptide Injection Protocol Overview

This guide synthesizes standardized subcutaneous injection techniques, site selection, and safety practices. Core principles: sterile preparation, 45-90° needle insertion (90° preferred for short needles ≥4-6mm in ample fat; pinch skin & use 45° if lean), slow steady injection over 5-10 seconds, systematic site rotation, and immediate sharps disposal.

Preparation & Supplies

• Hand Hygiene: Wash thoroughly with soap and water.
• Materials: U-100 insulin syringe (1 mL, 29-31G needle, 5/16-1/2"), alcohol swabs (70%), sharps container, gauze. Use 30-50 unit syringes for volumes <10 units.
• Vial Prep: Wipe stopper, dry 10-30 seconds, draw dose, tap out air bubbles. Warm vials to room temperature to reduce stinging.
• Volume Limit: ≤1.5 mL per site; split larger doses (e.g., 75 IU into 3x25 IU). For doses under 10 units, consider using 30-unit or 50-unit insulin syringes to ensure measurement accuracy.

Site Selection & Rotation

Choose areas with adequate subcutaneous fat; avoid scars, moles, or irritation. Systematically rotate sites 1-1.5 inches apart; avoid same spot for 1-2 weeks. Log sites to prevent lipohypertrophy/lumping:

• Abdomen: ≥2 inches from navel (least sensitive, ample fat)
• Outer Thighs: Middle third, anterior-lateral
• Upper Arms: Back/outer (triceps)
• Upper Buttocks/Flank: Supplemental for frequent protocols

Peptide Injection Technique

Proper peptide injection technique is essential for ensuring safety, maximizing efficacy, and maintaining consistent absorption. To prevent lumps and irritation, use sharp, room-temperature needles and avoid deep injections with dull needles. Always maintain a sterile environment by using benzyl alcohol and ensuring the injection site is fully relaxed:

1. Clean site outward in circles; air-dry 30 seconds.
2. Pinch 1-2 inch skin fold to lift subcutaneous layer.
3. Insert needle at 45-90° angle (90° for ample fat, 45° for lean/thin needle).
4. No aspiration (pulling back plunger to check for blood)
5. Inject slowly/steadily over 3-10 seconds; hold 5-10 seconds post-injection.
6. Withdraw at same angle; gentle pressure if bleeding.
7. Dispose in sharps container immediately; never recap.
8. Discard any reconstituted solution if it becomes cloudy. Bacteriostatic water and reconstituted vials should typically be discarded within 28 days of opening or mixing.

Peptide Injection Timing Consideration

• Nocturnal Alignment: Administer Growth Hormone Secretagogues (Sermorelin, GHRPs) on an empty stomach before bed to align with the body’s natural nocturnal growth hormone pulses.
• Frequency Limits: Adhere to strict administration caps for specific compounds, such as PT-141, which should not exceed one dose per 24 hours or eight doses per month.
• Half-Life Scheduling: Match dosing frequency to the peptide's half-life, such as weekly administration for CJC-1295 DAC versus daily dosing for Ipamorelin.
• Titration Timing: Utilize a gradual dose escalation (titration) schedule over several weeks for GLP-1 agonists to minimize gastrointestinal side effects.
• Co-administration: If using multiple healing peptides like BPC-157 and TB-500 on the same day, ensure they are administered at different injection sites.
• Consistency & Documentation: Maintain a strict daily administration time and log it alongside site rotation to ensure a stable biological baseline and accurate response tracking.

Peptide Post-Injection Care & Risks

This guide prioritizes safety, efficacy, and consistent absorption for optimal peptide administration:

• Monitor for redness/swelling; rest site 1-7 days if severe.
• No massage (disrupts absorption).
• Document dose, site, time, reactions.
• Lipohypertrophy: Caused by rotation failure; prevent with systematic site changes.
• Pain/Lumps: From deep injection, cold solution, or dull needles.
• Infection: Maintain asepsis; monitor for fever/redness.

Tesofensine – Identification

Common Name(s): Tesofensine, Tesofensine free base, NS-2330, NS2330, NS 2330, CL-201, Tesofensin, Tesufensin

CAS Number: 195875-84-4 (free base)

CAS Number (Citrate Salt): 861205-83-6

Molecular Formula (Free Base): C₁₇H₂₃Cl₂NO

Molecular Weight: 328.28 Da (free base); approximately 520.40 Da (citrate salt form)

FDA UNII: BLH9UKX9V1

Origin & Type Classification:

• Source: Synthetic; not naturally occurring in biological systems

• Biosynthesis: Nonribosomal small-molecule synthesis via organic chemistry methodologies

• Functional Class: Central nervous system active agent, triple monoamine reuptake inhibitor, appetite suppressant, antiobesity agent, neurochemical modulator

Structural Classification:

The compound belongs to the phenyltropane class of chemicals, characterized by a bicyclic 8-azabicyclo[3.2.1]octane (norbornane-like) core structure with a 3,4-dichlorophenyl substituent and an ethoxymethyl side chain.

Detailed Chemical Structure:

IUPAC Name: (1R,2R,3S,5S)-3-(3,4-dichlorophenyl)-2-(ethoxymethyl)-8-methyl-8-azabicyclo[3.2.1]octane

Skeletal Structure Components:

• Core Structure: 8-Methyl-8-azabicyclo[3.2.1]octane (norbornane-like scaffold with nitrogen bridgehead)

• Aromatic Substituent: 3,4-Dichlorophenyl group (two chlorine atoms at meta and para positions of benzene ring), attached at position 3

• Alkyl Substituent: Ethoxymethyl group (−CH₂OCH₂CH₃), attached at position 2

• Stereochemistry: Four defined chiral centers with the stereochemical configuration (1R,2R,3S,5S)

Single-Letter Code (SMILES): CN1[C@@H]2CC@HC@@H[C@H]1CC2

InChI: InChI=1S/C17H23Cl2NO/c1-3-21-10-14-13(9-12-5-7-17(14)20(12)2)11-4-6-15(18)16(19)8-11/h4,6,8,12-14,17H,3,5,7,9-10H2,1-2H3/t12-,13+,14+,17+/m0/s1

Physical Properties:

• Physical Form: White to off-white sticky solid or powder

• Solubility:

  • DMF: 2 mg/mL

  • DMSO: 1 mg/mL

  • Ethanol: Slightly soluble

  • PBS (pH 7.2): 0.14 mg/mL

  • Water: Sparingly soluble

• Density: 1.161 ± 0.06 g/cm³ (predicted)

• Boiling Point: 396.6 ± 42.0°C (predicted)

• pKa: 10.46 ± 0.60 (predicted)

• Melting Point: Not formally established; decomposition temperature range not specifically reported

• Color: White to off-white

• Stability: Hygroscopic; sensitive to moisture

• Storage: −20°C for long-term storage (≥3 years); −80°C for extended storage in solution (≥1 year)

Pharmacokinetic Parameters:

• Elimination Half-Life: Approximately 9 days (216 hours) in humans

• Primary Active Metabolite: Desalkyl metabolite (NS2360/N-demethyl metabolite), with half-life ~16 days (384 hours); approximately 31–34% of parent drug exposure at steady state

• Metabolism: Primarily metabolized by cytochrome P450 3A4 (CYP3A4) to N-desmethyl metabolite through N-oxidative dealkylation

• Renal Clearance: Minimal renal elimination; approximately 15–20% of total clearance

• Bioavailability: Incomplete for oral administration; variable absorption with food effects potentially present

• Absorption: Oral route

Receptor Binding and Transporter Inhibition:

Tesofensine exhibits inhibitory activity across three presynaptic monoamine transporters with differential selectivity:

• Dopamine Transporter (DAT): IC₅₀ = 6.5 nM

• Norepinephrine Transporter (NET): IC₅₀ = 1.7 nM (highest potency)

• Serotonin Transporter (SERT): IC₅₀ = 11 nM

The NET-selective potency (approximately 4-fold higher than DAT and 6-fold higher than SERT) indicates that norepinephrine system modulation represents the primary pharmacological action, though the balanced triple-reuptake-inhibition profile distinguishes tesofensine from selective or dual inhibitors.

Salt Forms & Formulations:

Tesofensine is supplied commercially in multiple salt forms:

• Free Base (powder for research use)

• Citrate Salt (CAS 861205-83-6; pharmaceutical formulation)

• Hydrochloride Salt (potential formulation; not widely documented)

Synonyms in Literature & Trade Names:

• GW327830 (development code)

• NeuroSearch 2330

• NS 2330

• CL-201

• Tesofensin

• Tesufensin

Database Links & Identifiers:

• PubChem CID: 11370864 (free base)

• DrugBank ID: DB06156

• ChEMBL ID: CHEMBL514514

• InChIKey: VCVWXKKWDOJNIT-ZOMKSWQUSA-N

• MDL Number: MFCD25976398

Tesofensine – Research

Tesofensine operates as a potent triple monoamine reuptake inhibitor—blocking dopamine, norepinephrine, and serotonin uptake—to curb appetite at hypothalamic levels, notably by silencing GABAergic neurons in the lateral hypothalamus that drive feeding behavior. This yields superior weight loss of 9-10.6% over 24 weeks in obese patients (twice sibutramine's effect), fueled by profound satiety, reduced hunger ratings, and elevated energy expenditure without taste aversion or locomotion dependency. Phase II trials confirmed dose-dependent fat mass erosion (6.7 kg at 1 mg), lean mass preservation, waist reductions, and insulin sensitivity boosts, with mild heart rate increases (8 bpm max) but neutral blood pressure. In high-fat diet models, it outperforms in obese versus lean subjects, synergizes with GLP-1 agonists, and prevents rebound via serotonergic pairing—low abuse liability stems from minimal phentermine-like stereotypy. Though phase III halted over regulatory cardiac concerns, its anorexigenic-metabolic duality positions it for obesity adjunctive roles.

Study: Effect of tesofensine on bodyweight loss, body composition, and safety in obese patients
Benefits: Drives 9.2-10.6% total weight loss (0.5-1.0 mg doses) versus 2% placebo over 24 weeks on calorie restriction, with 6.7 kg fat loss and cardiometabolic gains.
Link: https://pubmed.ncbi.nlm.nih.gov/18950853/
Summary: Across 203 obese adults (BMI 30-40 kg/m²), tesofensine scaled weight reductions dose-dependently, halving fat mass while safeguarding muscle, shrinking waists, and optimizing triglycerides/insulin. Heart rate rose modestly without dropout spikes (21% overall), evidencing a potency-safety profile eclipsing approved agents and validating central monoamine modulation for sustained obesity intervention.

Study: Weight loss produced by tesofensine in patients with obesity
Benefits: Nets ~4% placebo-subtracted loss in 14 weeks sans lifestyle changes, mirroring sibutramine efficacy minus hypertension risks.
Link: https://pubmed.ncbi.nlm.nih.gov/18356831/
Summary: Early human data pinpointed appetite suppression as the core driver, with metabolic uplifts suggesting repurposing potential from Parkinson's origins—laying groundwork for tesofensine's obesity pivot through balanced neurotransmitter enhancement.

Study: Tesofensine induces appetite suppression and weight loss with superior effects in obese rats
Benefits: Excels in diet-induced obesity via hypothalamic GABA silencing, blocks post-serotonergic rebound, no palatability disruption.
Link: https://pubmed.ncbi.nlm.nih.gov/23932919/
Summary: Rodent studies revealed amplified anorexigenic potency in obese states (higher metabolic ratio), with lateral hypothalamus targeting explaining human translations—serotonergic combos extended effects, forecasting hybrid therapies for weight maintenance.

Study: Tesofensine, a novel antiobesity drug, silences GABAergic neurons in the Lateral Hypothalamus
Benefits: Suppresses feeding-promoting GABA cells, augments GLP-1 loss, low stereotypy versus stimulants.
Link: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0300544
Summary: Optogenetic validation confirmed neuronal specificity, boosting obese outcomes without aversion—minimal abuse signals enhance its profile for combo regimens targeting intractable obesity circuits.

Tesofensine's hypothalamic precision unleashes 9-11% losses via appetite-energy synergy, trumping peers in obese models with rebound-proof potential, despite stalled approval.

Tesofensine – Research Links